Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys

Biologicals

Volumn 33, Issue 3, 2005, Pages 131-144

  Monath, Thomas P ^a   Myers, Gwendolyn A ^a   Beck, Robert A ^a   Knauber, Michael ^a   Scappaticci, Kelly ^a   Pullano, Thad ^a   Archambault, W Tad ^b   Catalan, John ^a   Miller, Chuck ^a   Zhang, Zhen Xi ^a   Shin, Sunheang ^a   Pugachev, Konstantin ^a   Draper, Ken ^c   Levenbook, Inessa S ^d   Guirakhoo, Farshad ^a  

^a Acambis   (United States)

^b Virtu Stat Ltd   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERI VAX; FLAVIVIRUS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; YELLOW FEVER VACCINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE CALCULATION; DRUG SAFETY; FEMALE; INFECTION PREVENTION; INOCULATION; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SPECIES COMPARISON; STRAIN DIFFERENCE; SURVIVAL RATE; VALIDATION PROCESS; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS VIRULENCE;

ANIMAL USE ALTERNATIVES; ANIMALS; ANIMALS, NEWBORN; CENTRAL NERVOUS SYSTEM; CERCOPITHECUS AETHIOPS; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HAPLORHINI; MICE; SENSITIVITY AND SPECIFICITY; VERO CELLS; VIRAL VACCINES; VIRULENCE;

FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; PRIMATES; WEST NILE VIRUS; YELLOW FEVER VIRUS (STRAIN 17D);

EID: 23944433685     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2005.03.009     Document Type: Article

References (32)

1. A.W. Sellards Behavior of the virus of yellow fever in monkeys and mice Proc Natl Acad Sci U S A 17 1931 339 343
2. T.P. Monath Yellow fever: empiricism to molecular virology S. Plotkin B. Fantini Vaccinia, vaccines and vaccinology 1996 Elsevier Paris 157 182
3. J.P. Fox, and H.A. Penna Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose, and neural or extraneural inoculation Am J Hyg 38 1943 152 172
4. F. Liprandi Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus J Gen Virol 56 1981 363
5. J.L. Melnick, M. Benyesh-Melnick, and J.C. Brennan Studies on live poliovirus vaccine: its neurotropic activity in monkeys and its increased neurovirulence after multiplication in vaccinated children JAMA 171 1959 1165 1172
6. R. Murray, R. Kirschstein, G. van Hoosier, and S. Baron Comparative virulence for rhesus monkeys of poliovirus strains used for oral administration Proceedings of the first international conference on live poliovirus vaccines 1959 Pan American Sanitary Bureau Washington, DC 39 64
7. N. Nathanson, and S.D. Horn Neurovirulence tests of type 3 poliovirus vaccine manufactured by Lederle Laboratories, 1964-1988 Vaccine 10 1992 469 474
8. S.S. Marennikova, K.L. Chimishkyan, N.N. Maltseva, E.M. Shelukhina, and V.V. Fedorov B. Gusic Proceedings of the symposium on smallpox, 2 & 3 September 1969 1969 Yugoslav Academy of Sciences and Arts Zagreb 65 79
9. Levenbook IS, Robinzon IA, Rozina EE, Chigirinsky AE, Tsetlin EM, Rukhamina ML, et al. Pathomorphology of the process caused by smallpox vaccine strains in monkeys. XVI All-Union Meeting of Microbiologists and Epidemiologists, part 3, p. 46-7, 1977, Moscow, Russia [in Russian].
10. I.S. Levenbuk, M.A. Nikolayeva, A.E. Chigirinsky, N.M. Ralf, V.G. Koslov, and N.V. Vardanyan On the morphological evaluation of the neurovirulence safety of attenuated mumps virus strains J Biol Stand 7 1979 9 19
11. N. Nathanson, D. Goldblatt, I.S. Thind, M. Davis, and W.H. Price Histological studies of the money neurovirulence of group B arboviruses. I. A semi-quantitative grading scale Am J Epidemiol 82 1965 359 381
12. N. Nathanson, M. Davis, I.S. Thind, and W.H. Price Histological studies of the monkey neurovirulence of group B arboviruses. II. Selection of indicator centers Am J Epidemiol 84 1966 524 540
13. I.S. Levenbook, L.J. Pelleu, and B.L. Elisberg The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination J Biol Stand 15 1987 305 313
14. World Health Organization. Requirements for yellow fever vaccine (Requirements for biological substances no. 3). Tech Rep Ser, WHO, Geneva; 1997.
15. R.S. Marchevsky, M.S. Freire, E.S.F. Coutinho, and R. Galler Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys Virology 316 2003 55 63
16. T.J. Chambers, A. Nestorowicz, P.W. Mason, K.H. Eckels, and C.M. Rice Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties J Virol 73 1999 3095 3101
17. F. Guirakhoo, Z. Zhang, T.J. Chambers, S. Delagrave, J. Arroyo, and A.D.T. Barrett Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis Virology 257 1999 363 372
18. J. Arroyo, C. Miller, J. Catalan, G.A. Myers, M. Ratterree, and D.W. Trent ChimeriVax™-West Nile live-attenuated vaccine: preclinical evaluation of safety, immunogenicity and efficacy J Virol 78 2004 12497 12507
19. T.P. Monath, Soike, I. Levenbook, Z.-X. Zhang, J. Arroyo, and S. Delagrave Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates Vaccine 17 1999 1869 1882
20. T.P. Monath, K. Soike, Z.-X. Zhang, M. Ratterree, K. Draper, and A.D.T. Barrett Live, attenuated recombinant chimeric yellow fever-Japanese encephalitis vaccine: extended safety and immunogenicity studies in rhesus monkeys J Virol 74 2000 1742 1751
21. F. Guirakhoo, J. Arroyo, K.V. Pugachev, C. Miller, Z.-X. Zhang, and R. Weltzin Construction, safety, and immunogenicity in non-human primates of a chimeric yellow fever-dengue tetravalent vaccine J Virol 75 2001 7290 7304
22. T.P. Monath, J. Arroyo, I. Levenbook, Z.-X. Zhang, J. Catalan, and K. Draper Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines J Virol 76 2002 1932 1943
23. F. Guirakhoo, Z. Zhang, G. Myers, B.W. Johnson, K. Pugachev, and R. Nichols A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys J Virol 78 2004 9998 10008
24. J. Arroyo, F. Guirakhoo, S. Fenner, Z.-X. Zhang, T.P. Monath, and T.J. Chambers Molecular basis for attenuation of neurovirulence of a yellow fever/Japanese encephalitis (ChimeriVax-JE) viral vaccine J Virol 75 2001 934 942
25. F. Guirakhoo, R. Weltzin, T.J. Chambers, Z.X. Zhang, K. Soike, and M. Ratterree Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates J Virol 74 2000 5477 5485
26. L.J. Reed, and H. Muench Simple method of estimating fifty percent endpoints Am J Hyg 27 1938 493 497
27. T.P. Monath, F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, and C. Murphy Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen J Infect Dis 188 2003 1213 1230
28. T.P. Monath, C.B. Cropp, G.S. Bowen, G.E. Kemp, C.J. Mitchell, and J.J. Gardner Variation in virulence for mice and rhesus monkeys among St. Louis encephalitis virus strains of different origin Am J Trop Med Hyg 29 1980 948 962
29. M. Theiler The virus G.K. Strode Yellow fever 1951 McGraw-Hill New York 39 136
30. C.J. Lai, and T.P. Monath Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis T.J. Chambers T.P. Monath The flaviviruses: detection, diagnosis, and vaccine development Adv Virus Res 61 2003 470 509
31. D. Wood Neurovirulence Dev Biol Stand 101 1999 127 129
32. K.M. Chumakov, L.P. Norwood, M.L. Parker, E.M. Dragunsky, Y.X. Ran, and I.S. Levenbook RNA sequence variants in live poliovirus vaccine and their relationship to neurovirulence J Virol 66 1992 966 970